To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine
Initiator Pharma A/S, a clinical-stage biotech company, today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company’s patented candidate drug IP2015, which is in clinical development in erectile dysfunction and neuropathic pain.
Initiator Pharma A/S – Resolutions of the annual general meeting 2023
The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 26 May 2023 at 10.00 AM CEST.
INITIATOR PHARMA: Q1 2023 REPORT
Business highlights in Q1 2023 In March the Company announced the completion of dosing of all 24 patients the the Phase IIa clinical trial with IP2018 and that preliminary results are expected end…
Annual report and Remuneration report 2022 for Initiator Pharma A/S
Initiator Pharma’s Annual Report 2022 and Remuneration Report 2022 has now been published and is available on the company´s home page.
Initiator Pharma completes dosing in Phase 2a trial with IP2018
Initiator Pharma A/S, a clinical-stage biotech company, today announced that it has completed dosing all 24 patients for its Phase 2a clinical trial with IP2018. Draft results are expected end of Q2 2023, as previously communicated.